Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K. Hilton, David W. Scott, Henry S. Ngu et al.|Journal of Clinical Oncology|2023Cited by 50
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.Sagar Lonial, Monique C. Minnema, Thierry Façon et al.|Journal of Clinical Oncology|2022Cited by 25